Skip to content

Medneed

  • All Offers
  • Find a Provider
  • Coverage & Payment
  • Devices & Equipment
  • Drugs & Supplements
Drugs and Supplements Newly Approved Ulcerative Colitis

Velsipity to treat active ulcerative colitis in adults

ulcerative colitis

Drug Name: Velsipity

Active Ingredient: etrasimod

Indication: To treat moderately to severely active ulcerative colitis in adults

Approval Date: 10/12/2023

Company: Pfizer Inc

More: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-fda-and-ema-acceptance-etrasimod

Related

Post navigation

VARIVAX vaccine for the prevention of varicella, 12 months of age and older.
Merck’s Keytruda gets FDA nod for expanded use in lung cancer

Related

Drugs and Supplements Practice Process Professional Research

Elevating Healthcare Conversations through AI-Enabled CI: KAI Conversations

Drugs and Supplements Practice Process Professional Research

Revolutionizing Pharmacovigilance with AI: DrugCard

Drugs and Supplements Practice Procedure Process Professional Research

Solving for Precision Medicine with AI-Enabled Solutions: Tempus

Categories
Archives

Medneed empowers users to reliably discover and afford innovative solutions they need to solve complex cases, optimize processes, and achieve superior health outcomes.

admin@medneed.com

  • Reviews & Publications
  • Receive Guidance
  • Enroll in Course
  • Join Events
  • About
  • Contact
  • Neuro Research Initiative
  • Privacy Policy
  • Terms and Conditions

Medneed

© Copyright 2022 Medneed. All Rights Reserved.